Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

Although brain metastases occur in almost one-third of non-small cell lung cancer (NSCLC) patients, and immune checkpoint inhibitors (ICI) either as monotherapy or combined with chemotherapy are the new standard of care in the first line setting, most trials excluded patients with asymptomatic and/o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendriks, Lizza E. L., Remon, Jordi, Menis, Jessica, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264345/
https://www.ncbi.nlm.nih.gov/pubmed/34295685
http://dx.doi.org/10.21037/tlcr-20-343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264345/
https://www.ncbi.nlm.nih.gov/pubmed/34295685
http://dx.doi.org/10.21037/tlcr-20-343

Ejemplares similares